Shorts in AIDX have beaten a rapid retreat this week, even as the stock itself continues to drift lower — a divergence that sets an unusual backdrop heading into the post-earnings period.
The clearest story is the speed of the short-side unwind. Estimated short interest has fallen roughly 48% over the past week to around 16,400 shares, and is down nearly 50% from a month ago. That follows an especially turbulent few months: cost to borrow peaked above 200% in early April before beginning a sharp descent, and it has now collapsed to 34% — still elevated for most stocks, but a fraction of where it was six weeks ago. Availability has opened up dramatically, with the lending pool now loose relative to current short interest. The ORTEX short score has also retreated, dropping from a recent peak near 50 to 38.5 as of May 14 — a meaningful move lower over just a few sessions.
Price action tells a conflicting story. The stock closed at $1.34 on May 15, down around 22% over the past month and off another 2–3% on the week. Short sellers may be exiting, but buyers have not stepped in with any conviction. The company carries a micro-cap market cap of roughly $14 million, which means even modest share movements can produce outsized readings on borrow and utilisation data; the absolute figures here — tens of thousands of shares rather than millions — should be read in that context.
The fundamental catalyst this week was a May 12 licensing agreement with the University of South Carolina for the commercialisation of a patented algorithm to evaluate prostate-specific antigen level changes. The deal puts a commercial footing under AIDX's core technology. That announcement landed just ahead of what appears to have been an earnings event on May 15. The most recent comparable earnings release — March 31 — produced a 1-day gain of 5.6% and a 5-day move of 7.3%, suggesting the stock can react positively to catalysts when sentiment lines up.
Maxim Group initiated coverage on May 11 with a Buy rating and a $5 price target. The note lands against a stock trading at $1.34. That gap warrants caution: the target is nearly four times the current price, and with no other recent analyst coverage on record, the Street picture is thin. Institutional ownership is concentrated — Jonathan Cohen holds roughly 13% of shares, and Ping An Asset Management another 6%, with only 11 reported institutional holders in total. That concentration can amplify volatility in either direction when conditions shift.
What to watch next is whether the post-earnings price action stabilises around current levels or continues to erode — the borrow unwind suggests short-side pressure has largely cleared, but the stock needs a fresh fundamental or newsflow catalyst to reverse a month of steady losses.
See the live data behind this article on ORTEX.
Open AIDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
